Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 14
Submit an article Journal homepage
251
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels

Massimo C Mauri University of Milan, Clinical Psychiatry Department, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore, Milan, Italy
, MD,
Lucia S Volonteri University of Milan, Clinical Psychiatry Department, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore, Milan, Italy
, MD,
Alessio Fiorentini University of Milan, Clinical Psychiatry Department, Clinical Neuropsychopharmacology Unit, Fondazione IRCCS Ospedale Maggiore, Milan, Italy
, MD,
Rodolfo Pirola University of Milan, Department of Pharmacology, School of Medicine, Via Vanvitelli 32, 20129 Milano, Italy
, PhD &
Silvio R Bareggi University of Milan, Department of Pharmacology, School of Medicine, Via Vanvitelli 32, 20129 Milano, Italy + 39 02 5031 6946; + 39 02 5031 6949; [email protected]
, MD PhD
Pages 2207-2213 | Published online: 10 Oct 2007

Bibliography

  • GEFVERT O, LUNDBERG T, WIESELGREN IM et al.: D2 and 5-HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. (2001) 11:105-110.
  • DE VANE CL, NEMEROFF CB: Clinical pharmacokinetics of quetiapine. Clin. Pharmacokinet. (2001) 40:509-522.
  • HELLEWELL JSE, CAMERON HANDS D, MCKELLAR J: Seroquel: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range. Schizophr. Res. (1998) 29:154.
  • GUNASEKARA NS, SPENCER CM: Quetiapine. A review of its use in schizophrenia. CNS Drugs (1998) 9:325-340.
  • SMALL JG, HIRSCH SR, ARVANTIS LA et al.: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54:549-557.
  • ARVANTIS LA, MILLER BG: Multiple fixed doses of seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol. Psychiatry (1997) 42:233-246.
  • BORISON RI, ARVANTIS LA, MILLER BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel group. J. Clin. Psychopharmacol. (1996) 16:158-169.
  • PEUSKENS J, LINK CGC: A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. (1997) 96:265-273.
  • COPOLOV DL, LINK CGC, KOWALCYK B: A multicentre, double-blind randomized comparison of quetiapine and haloperidol in schizophrenia. Psychol. Med. (2000) 30:95-105.
  • SCHULZ SC, THOMPSON R, BRECHER M: The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy. Schizophr. Res. (2003) 62:1-12.
  • TANDON R, JIBSON MD: Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology (2003) 28(Suppl. 1):9-26.
  • CHENGAPPA KN, GOLDSTEIN JM, GREENWOOD M et al.: A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin. Ther. (2003) 25:530-541.
  • CHENGAPPA KN, EBELING T, KANG JS et al.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J. Clin. Psychiatry (1999) 60:477-484.
  • KHOUZAM HR, DONNELLY NJ: Remission of self-mutilation in a patient with borderline personality disorder during risperidone therapy. J. Nerv. Ment. Dis. (1997) 185:348-349.
  • ZANARINI MC, FRANKENBURG FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo controlled pilot study. J. Clin. Psychiatry (2001) 62:849-854.
  • ZANARINI MC, FRANKENBURG FR, PARACHINI EA: A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry (2004) 65:903-904.
  • NICKEL MK, MUEHLBACHER M, NICKEL C et al.: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry (2006) 163(5):833-838.
  • ADITYANJEE, SCHULZ SC: Clinical use of quetiapine in disease states other than schizophrenia. J. Clin. Psychiatry (2002) 63(Suppl. 16):32-38.
  • HILGER E, BARNAS C, KASPER S: Quetiapine in the treatment of borderline personality disorder. World J. Biol. Psychiatry (2003) 4:42-44.
  • VILLENEUVE E, LEMELIN S: Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J. Clin. Psychiatry (2005) 66(10):1298-1303.
  • PERRELLA C, CARRUS D, COSTA E, SCHIFANO F: Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31(1):158-163.
  • ALBANESE MJ: Safety and efficacy of risperidone in substance abusers with psychosis. Am. J. Addict. (2001) 10:190-191.
  • SATTAR SP, GRANT K, BHATIA S, PETTY F: Potential use of olanzapine in treatment of substance dependence disorders. J. Clin. Psychopharmacol. (2003) 23:413-415.
  • SATTAR SP, BHATIA SC: Olanzapine for cocaine cravings and relapse prevention. J. Clin. Psychiatry (2003) 64:969.
  • ZIMMET SV, STROUS RD, BURGESS ES: Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J. Clin. Psychopharmacol. (2000) 20:94-98.
  • MISRA L, KOFOED L: Risperidone treatment of methamphetamine psychosis. Am. J. Psychiatry (1997) 154:1170.
  • MISRA LK, KOFOED L, OESTERHELD J, RICHARDS G: Olanzapine treatment of methamphetamine psychosis. J. Clin. Psychopharmacol. (2000) 20:393-394.
  • SATTAR SP, BHATIA SC, PETTY F: Potential benefits of quetiapine in the treatment of substance dependence disorders. J. Psychiatry Neurosci. (2004) 29:452-457.
  • FABRE JR, ARVANITIS L, PULTZ J et al.: ICI 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin. Ther. (1995) 17:366-378.
  • American psychiatric association: Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC (2000).
  • OVERALL JE, GORHAM DR: The brief psychiatric rating scale. Psychol. Rep. (1962) 10:799-812.
  • KAY SR, FISZBEIN A, OPLER LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. (1987) 13:261-276.
  • HAMILTON M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry (1960) 23:56-62.
  • SIMPSON RM, ANGUS JSW: A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. (1970) 212:11-19.
  • MANDRIOLI R, FANALI S, FERRANTI A, RAGGI MA: HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J. Pharm. Biomed. Anal. (2002) 30:969-977.
  • HELLEWELL J, CANTILLION M, MCKELLAR M: “Seroquel”: efficacy in aggression, hostility and low mood of schizophrenia. Int. J. Neuropsychopharmacol. (1999) 2(Suppl. 1):S112.
  • SAJATOVIC M, MULLEN JA, SWEITZER DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J. Clin. Psychiatry (2002) 63:1156-1163.
  • GOLDSTEIN J: Quetiapine fumarate (seroquel): a new atypical antipsychotic. Drug Today (1999) 35:193-210.
  • CHEER SM, WAGSTAFF AJ: Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs (2000) 18:173-199.
  • JONES AM, RAK IW, RANIWALLA J et al.: Weight changes in patients treated with ‘Seroquel’ (quetiapine). Schizophr. Res. (2000) 41:83.
  • DAVIS PC, WONG J, GEVFERT O: Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J. Pharm. Biomed. Anal. (1999) 20:271-282.
  • THYRUM PT, FABRE LF, WONG YWJ: Multiple dose pharmacokinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacol. Bull. (2003) 32:525.
  • THYRUM PT, WONG YW, YEH C: Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry (2000) 24:521-533.
  • WONG J, EWING B, THYRUM P et al.: Kinetics of Seroquel in hepatic and renal insufficiency. 10th World Congress of Psychiatry. Madrid 2 (1996):300.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.